---
title: Procyanidin B2 Enriched Cocoa Effects on Mitochondrial Biogenesis
nct_id: NCT04301583
overall_status: COMPLETED
phase: NA
sponsor: Universidad Europea de Madrid
study_type: INTERVENTIONAL
primary_condition: Athletes
countries: Spain
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04301583.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04301583"
ct_last_update_post_date: 2020-11-04
last_seen_at: "2026-05-12T06:20:11.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Procyanidin B2 Enriched Cocoa Effects on Mitochondrial Biogenesis

**NCT ID:** [NCT04301583](https://clinicaltrials.gov/study/NCT04301583)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 38
- **Lead Sponsor:** Universidad Europea de Madrid
- **Conditions:** Athletes
- **Start Date:** 2020-06-01
- **Completion Date:** 2020-09-01
- **CT.gov Last Update:** 2020-11-04

## Brief Summary

The purpose of this study is to test how cocoa-rich procyanidin B2 affect the mitochondrial exercise adaptations.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 45 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Men/Women
* Age between 18 and 45 years
* Aerobic power of oxygen consumption greater than or equal to 55 mL / kg / min

Exclusion Criteria:

* Smoke
* Any chronic disease
* Intake of nutritional or ergogenic supplements
* Chronic medication
* Cocoa allergy
```

## Arms

- **Procyanidin B2 enriched cocoa** (ACTIVE_COMPARATOR) — Participants receiving cocoa capsules
- **Placebo group** (PLACEBO_COMPARATOR) — Participants maltodextrin capsules

## Interventions

- **procyanidin B2 enriched cocoa** (DIETARY_SUPPLEMENT) — Volunteers will intake 5 grams per day of dietary supplement for 10 weeks

## Primary Outcomes

- **Difference in mitochondrial number** _(time frame: 10 weeks)_ — Number of mitochondria in blood cells measured by qPCR using mitochondrial COX1 gene and beta globin as housekeeping nuclear gene
- **Difference in exercise performance** _(time frame: 10 weeks)_ — Maximum oxygen consumption

* of incomplete pulmonary gas exchange on VO2 max - Powers - Citado por 318
* determination of cardiorespiratory fitness and training … - Clark - Citado por 180 Maximum oxygen consumption

## Locations (1)

- Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.universidad europea de madrid|villaviciosa de odón|madrid|spain` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04301583.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04301583*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*